ProCE Banner Activity

BRUIN 2-Yr Update: Phase I/II Trial Evaluating Pirtobrutinib in Covalent BTKi–Treated MCL

Conference Coverage
Slideset

After approximately 2 years of follow-up, pirtobrutinib continues to demonstrate a high response rate with durable responses and a manageable safety profile in patients with heavily pretreated MCL, including in patients who previously received a covalent BTK inhibitor.

Released: June 09, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AbbVie, Geron, Jazz Pharmaceuticals, Lilly, Merck Sharp & Dohme Corp., and Novartis.

AbbVie

Geron

Jazz Pharmaceuticals

Lilly

Merck Sharp & Dohme Corp.

Novartis